Phaim Pharma Ltd.
Previously recorded as Dmnomore (to 2022)
When these terms end
Fee deadlines
No maintenance fee falls due on this company's record before Nov 18, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Showing 1 to 2 of 2
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,233,242 | CTLA4 Fusion Proteins for the Treatment of Diabetes In force · Low confidence | In force | Low confidence | |
| US 11,040,093 | Immunomodulatory Therapy for Type 1 Diabetes Mellitus Autoimmunity In force · High confidence | In force | High confidence |
Sources and methods
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 pending · 2 abandoned · 4 no status recorded
Showing 1 to 8 of 8, newest filing first. An application has no patent term. A term is computed when and if it grants, and appears on that patent's own page. Where no title is shown, the bulk publication record carries none and this site holds no USPTO file history for that application.
| Application | Title | Filed | Status |
|---|---|---|---|
| 19/175,610 | Apr 10, 2025 | No status recorded | |
| 18/770,727 | Psoriasis and Other Autoimmune Diseases Antigen Immune Modulator (AIM) Therapeutic Platform | Jul 12, 2024 | Pending |
| 18/586,621 | Immunomodulatory Therapy For Type 1 Diabetes Mellitus Autoimmunity | Feb 26, 2024 | Pending |
| 18/140,214 | Apr 27, 2023 | No status recorded | |
| 18/183,465 | Mar 14, 2023 | No status recorded | |
| 18/571,294 | Jun 16, 2022 | No status recorded | |
| 17/358,760 | Psoriasis and Other Autoimmune Diseases Antigen Immune Modulator (AIM) Therapeutic Platform | Jun 25, 2021 | Abandoned |
| 17/336,410 | Immunomodulatory Therapy for Type 1 Diabetes Mellitus Autoimmunity | Jun 2, 2021 | Abandoned |